Hansa Biopharma, “Hansa”, today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of ...

Thanks to the relentless efforts of medical researchers around the world, several different messenger ribonucleic acid (mRNA) and vector-based vaccines were authorized for use by regulatory bodies ...

The FDA granted Pfizer a breakthrough therapy designation for its group B Streptococcus vaccine candidate for pregnant people to prevent GBS disease in newborns based on its ongoing phase 2 trial. GBS ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New surveillance data from the Vaccine Safety Datalink confirm a small but statistically ...

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy). The ...